<strong>As the scope of the RPI is to allow tracking of a medicinal product development across all its lifecycle, EMA holds a single RPI for every development product, across all indications and even if the product is transferred/sold to another organisations, or if a submission is prepared by a different organisation (e.g. a consultant). It is the responsibility of the holder of the RPI to transfer it to another organisation, which can be done quickly and easily in IRIS - the operation is automated (no EMA validation or assessment) and the transfer is almost instantaneous. The RPI can then be transferred back, or to another organisation, any number of times - there is no limit. </strong>